TY - JOUR
T1 - Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems
AU - Eichenlaub, Manuel
AU - Pleus, Stefan
AU - Rothenbühler, Martina
AU - Bailey, Timothy S.
AU - Bally, Lia
AU - Brazg, Ronald
AU - Bruttomesso, Daniela
AU - Diem, Peter
AU - Eriksson Boija, Elisabet
AU - Fokkert, Marion
AU - Haug, Cornelia
AU - Hinzmann, Rolf
AU - Jendle, Johan
AU - Klonoff, David C.
AU - Mader, Julia K.
AU - Makris, Konstantinos
AU - Moser, Othmar
AU - Nichols, James H.
AU - Nørgaard, Kirsten
AU - Pemberton, John
AU - Selvin, Elizabeth
AU - Spanou, Loukia
AU - Thomas, Andreas
AU - Tran, Nam K
AU - Witthauer, Lilian
AU - Slingerland, Robbert J
AU - Freckmann, Guido
PY - 2024
Y1 - 2024
N2 - Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to the lack of comprehensive guidelines for clinical study design. In particular, the absence of concise requirements for the distribution of comparator (reference) blood glucose (BG) concentrations and their rate of change (RoC) that are used to evaluate CGM performance, impairs comparability. For this article, several experts in the field of CGM performance testing have collaborated to propose characteristics of the distribution of comparator measurements that should be collected during CGM performance testing. Specifically, it is proposed that at least 7.5% of comparator BG concentrations are <70 mg/dL (3.9 mmol/L) and >300 mg/dL (16.7 mmol/L), respectively, and that at least 7.5% of BG-RoC combinations indicate fast BG changes with impending hypo- or hyperglycemia, respectively. These proposed characteristics of the comparator data can facilitate the harmonization of testing conditions across different studies and CGM systems and ensure that the most relevant scenarios representing real-life situations are established during performance testing. In addition, a study protocol and testing procedure for the manipulation of glucose levels are suggested that enable the collection of comparator data with these characteristics. This work is an important step toward establishing a future standard for the performance evaluation of CGM systems.
AB - Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to the lack of comprehensive guidelines for clinical study design. In particular, the absence of concise requirements for the distribution of comparator (reference) blood glucose (BG) concentrations and their rate of change (RoC) that are used to evaluate CGM performance, impairs comparability. For this article, several experts in the field of CGM performance testing have collaborated to propose characteristics of the distribution of comparator measurements that should be collected during CGM performance testing. Specifically, it is proposed that at least 7.5% of comparator BG concentrations are <70 mg/dL (3.9 mmol/L) and >300 mg/dL (16.7 mmol/L), respectively, and that at least 7.5% of BG-RoC combinations indicate fast BG changes with impending hypo- or hyperglycemia, respectively. These proposed characteristics of the comparator data can facilitate the harmonization of testing conditions across different studies and CGM systems and ensure that the most relevant scenarios representing real-life situations are established during performance testing. In addition, a study protocol and testing procedure for the manipulation of glucose levels are suggested that enable the collection of comparator data with these characteristics. This work is an important step toward establishing a future standard for the performance evaluation of CGM systems.
U2 - 10.1089/dia.2023.0465
DO - 10.1089/dia.2023.0465
M3 - Review
C2 - 38194227
VL - 26
SP - 263
EP - 275
JO - Diabetes Technology & Therapeutics
JF - Diabetes Technology & Therapeutics
SN - 1520-9156
IS - 4
ER -